The 20 Best Familial Prostate Cancer Doctors Near Me in Fresh Meadows, NY

As Senior Vice President of the Urology Service Line, Chair of theSmith Institute for Urology, and Chair of Urology at the Zucker Schoolof Medicine at Hofstra/Northwell, Samir Taneja, MD will establish hisclinical practice at Lenox Hill Hospital and Long Island Jewish MedicalCenter focused on the surgical management of prostate cancerand renal tumors. He is an expert in urologic oncology, renowned fortransforming the field of prostate cancer diagnosis and treatmentby improving methods of prostate imaging, cancer detection, anddisease localization. Having performed thousands of robotic, ablative,laparoscopic and open surgical procedures, his specific clinical focushas been in improving prostate cancer patient outcomes throughpioneering techniques for focal ablative therapy, refining surgicaltechniques for robotic prostatectomy and partial nephrectomy,devising accelerated recovery pathways for robotic prostatectomy/partial nephrectomy, and providing muti-modal surgical approachesfor patients with high risk and recurrent prostate cancer. As leader ofthe department, he will strive to ensure individualized care of urologicdisease through state-of-the-art surgical approaches and multi-disciplinary care.Prior to joining Northwell, Dr Taneja was a faculty member of NYUGrossman School of Medicine for 29-years as a tenured professorof urology, radiology, and biomedical engineering. Most recently heserved as Director of the Division of Urologic Oncology and ViceChair in the Department of Urology at NYU Langone Health, as well asGenitourinary Program Leader in the Perlmutter Cancer Center.Dr. Taneja has conducted extensive clinical research on the use ofimaging in prostate cancer and is considered a pioneer in the use ofMRI to diagnose and localize prostate cancer and the emerging field ofprostate cancer focal therapy. He has authored more than 250 articles,30 book chapters, and six textbooks and monographs on urologiccancer and surgery. He is the editor of Taneja's Complications ofUrologic Surgery: Prevention and Diagnosis, one of the most widely readtextbooks in American Urology. Dr. Taneja is rated as a Distinguished provider by MediFind in the treatment of Familial Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Prostatectomy, and Nephrectomy.

Joph Steckel is a Urologist in Lake Success, New York. Dr. Steckel is rated as a Distinguished provider by MediFind in the treatment of Familial Prostate Cancer. His top areas of expertise are Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, Chromophobe Renal Cell Carcinoma, Nephrectomy, and Reconstructive Urology Surgery.

Sang Sim is an Internal Medicine specialist and a Radiation Oncologist in New Hyde Park, New York. Dr. Sim is rated as a Distinguished provider by MediFind in the treatment of Familial Prostate Cancer. His top areas of expertise are Familial Prostate Cancer, Prostate Cancer, Laryngeal Cancer, and Endometrial Cancer.

Michael J. Schwartz, MD, is Chief of Urology at Long Island Jewish Medical Center and Director of Urology Services for Northwell Health's Central Region. Dr. Schwartz specializes in minimally invasive procedures to treat prostate cancer. He has vast experience in robotic-assisted radical prostatectomy, evolving surgical techniques over time to minimize treatment-related side effects. For qualifying prostate cancer patients, Dr. Schwartz also offers focal ablation therapies, using sophisticated image guidance and focal tissue ablation to eradicate prostate cancer with few side effects. He has additional expertise in urologic oncology and surgery to treat kidney, bladder, adrenal and testicular cancers. Becoming a doctor always felt natural to me, Dr. Schwartz says. I was always interested in helping others, and urology is a wonderful blend of both medical and surgical care, allowing for the development of long-term relationships with my patients. Dr. Schwartz earned his medical degree from Warren Alpert Medical School of Brown University and pursued his residency training in urology at New York-Presbyterian Hospital, Cornell. He received his fellowship training in advanced laparoscopic and endoscopic surgery at North Shore University Hospital and Long Island Jewish Medical Center. Dr. Schwartz values a team-based approach to care, working with radiologists, pathologists and medical oncologists to create individualized, evidence-based treatment plans. He also carefully listens to patients to meet their unique goals and preferences. In addition to treating prostate cancer, Dr. Schwartz is a pioneer in prostate cancer diagnosis. He was an early adopter of transperineal biopsy-which eliminates the infection risk associated with the prior transrectal method-and helped the Smith Institute of Urology transition to using that approach for all patients requiring prostate biopsy across Northwell Health. His research focuses on both diagnostics and treatment of prostate cancer, and he is involved with several clinical trials for focal therapy. He is a member of the American Urological Association and Society of Urologic Oncology. He is Associate Professor of Urology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. For Dr. Schwartz, one of the best parts of his job is getting to know his patients. I have the privilege of seeing their humanity, learning about their lives and discovering what's important to them, he says. Their experiences inspire me every day. Dr. Schwartz is rated as a Distinguished provider by MediFind in the treatment of Familial Prostate Cancer. His top areas of expertise are Familial Prostate Cancer, Prostate Cancer, Enlarged Prostate (BPH), Reconstructive Urology Surgery, and Nephrectomy.

"Xinhua Zhu, MD, PhD, is a medical oncologist and hematologist at Monter Cancer Center, where he specializes in treating genitourinary cancer, including cancer of the prostate, kidney, bladder and testicles. He focuses on compassionate, evidence-based care, rooted in his research background.""My research helps me think outside the box when creating treatment plans,"" says Dr. Zhu, ""and enables me to explain to patients the mechanisms behind the treatments I'm using."" His research interests include finding new treatment targets for generating hormone resistance in prostate cancer and metastatic castration-resistant prostate cancer, exploring biomarkers in bladder cancer to guide decisions about chemotherapy, exploring the mechanisms for kidney cancer metastasis, and investigating the effectiveness of immunotherapy for genitourinary cancers.Dr. Zhu earned his medical degree at Suzhou Medical College and practiced internal medicine in China. He obtained his PhD in cancer study at Shanghai Jiao Tong University School of Medicine, then moved to the United States for postdoctoral research training at Memorial Sloan Kettering Cancer Center, an internal medicine residency at Mount Sinai School of Medicine. He attended NYU School of Medicine for fellowship training in hematology and medical oncology.In 2013, he joined Northwell Health, where he regularly meets with a multidisciplinary group of pathologists, radiologists, radiation oncologists, surgical oncologists, geneticists and the Molecular Tumor Board to create treatment plans.As an associate professor at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, he twice received the Medical Oncology/Hematology Fellowship Program Teacher of the Year Award. Dr. Zhu is also a phase 1 cancer research program director at Monter Cancer Center. He is assistant investigator at the Feinstein Institutes for Medical Research, and a member of the American Society of Clinical Oncology, the American Association of Cancer Research, and the Principal Investigator for the Northwell Health NCI Community Oncology Research Program (NCORP)For Dr. Zhu, being able to pursue both scientific investigation and patient care is the best part of his work. ""I can take research from the bench to the bedside, providing people with the best possible treatments,"" he says.". Dr. Zhu is rated as a Distinguished provider by MediFind in the treatment of Familial Prostate Cancer. His top areas of expertise are Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, Prostate Cancer, and Clear Cell Sarcoma.

Kai Tsao, MD, MS, is the system chief of solid tumor oncology, medical director of the R.J. Zuckerberg Cancer Center, and medical director of the medical oncology prostate cancer program at the Northwell Cancer Institute. He specializes in cancers of the genitourinary organs and has more than a decade of clinical experience. His research focuses on the development of biomarkers and novel therapies for patients with genitourinary cancers.Dr. Tsao was inspired to become an oncologist after witnessing many close family and friends suffering from cancer. He completed medical school training at SUNY Downstate, an internal medicine residency at Long Island Jewish Medical Center, and a fellowship in hematology and medical oncology at Mount Sinai Hospital. He earned a master's degree in healthcare delivery leadership at Icahn School of Medicine at Mount Sinai and completed Lean Six Sigma training at Johns Hopkins.Prior to joining Northwell, Dr. Tsao served as medical director of the Ruttenberg Treatment Center, medical director of the medical oncology prostate cancer program, and physician leader for internal oncology collaborations at the Mount Sinai Hospital, Tisch Cancer Institute. In these roles, Dr. Tsao and his team built a cancer center that is patient centered, quality driven, scientifically innovative, and provided multi-disciplinary care to patients with cancer.For me, patient care much more than the cancer diagnosis and treatment. It is essential to address the many needs of our cancer patients: emotional well-being, social support, nutrition, physical activity, financial challenges and more. We aim to provide the best support for our patients, one at a time.Dr. Tsao is an accomplished physician-scientist who has authored more than 80 peer-reviewed publications in the field of genitourinary oncology. He serves as associate editor of Genitourinary Oncology, Frontiers in Oncology. His leadership in carrying out complex clinical trials in targeted therapies and immunotherapies positions his patients at the forefront of cutting-edge cancer research and patient-centered care.What I most enjoy every day is seeing patients under our care, despite the devastation of their cancer diagnosis, beating their cancer and living a life that was not considered a possibility years ago. Our mission at Northwell Cancer Institute is to make this a reality for every single patient. Dr. Tsao is rated as a Distinguished provider by MediFind in the treatment of Familial Prostate Cancer. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Orchiectomy, and Nephrectomy.

Elliot Paul is a Urologist in New Hyde Park, New York. Dr. Paul is rated as a Distinguished provider by MediFind in the treatment of Familial Prostate Cancer. His top areas of expertise are Kidney Stones, Enlarged Prostate (BPH), Perirenal Abscess, Ureteroscopy, and Prostatectomy.

Howard Scher is an Oncologist in New York, New York. Dr. Scher is rated as an Elite provider by MediFind in the treatment of Familial Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Bone Tumor, Orchiectomy, and Prostatectomy. Dr. Scher is currently accepting new patients.

Michael Morris is an Oncologist in New York, New York. Dr. Morris is rated as an Elite provider by MediFind in the treatment of Familial Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Vocal Cord Dysfunction, Hip Replacement, and Knee Replacement. Dr. Morris is currently accepting new patients.

Dana Rathkopf is an Oncologist in New York, New York. Dr. Rathkopf is rated as an Elite provider by MediFind in the treatment of Familial Prostate Cancer. Her top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Bone Tumor, Prostatectomy, and Orchiectomy. Dr. Rathkopf is currently accepting new patients.

Behfar Ehdaie is a Urologist in New York, New York. Dr. Ehdaie is rated as an Elite provider by MediFind in the treatment of Familial Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Bladder Cancer, Prostatectomy, and Cystectomy. Dr. Ehdaie is currently accepting new patients.

Ashutosh Tewari is a Urologist in New York, New York. Dr. Tewari is rated as an Elite provider by MediFind in the treatment of Familial Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Urinary Incontinence, Prostatectomy, and Vasectomy. Dr. Tewari is currently accepting new patients.

Gary Weiss is a Urologist in Great Neck, New York. Dr. Weiss is rated as an Advanced provider by MediFind in the treatment of Familial Prostate Cancer. His top areas of expertise are Enlarged Prostate (BPH), Urothelial Cancer, Non-Muscle Invasive Bladder Cancer, Ureteroscopy, and Prostatectomy.

Louis Kavoussi, MD, MBA, Director of teleintervention at Northwell. He is a world-renowned urologic surgeon who brings more than 30 years of specialized expertise in minimally invasive urological surgery. His area of focus includes treating a wide range of urologic diseases, including kidney obstructions, renal stones and urologic cancer. At the forefront of innovation, Dr. Kavoussi pioneered several new surgical techniques, including the first minimally invasive approaches to kidney surgery for kidney cancer and kidney donation. He was also part of the team that performed the first laparoscopic prostate removal for cancer. In 1999, Dr. Kavoussi received a Smithsonian Computerworld Permanent Collection award for his work in developing telerounding, the starting point of telehealth medicine-to facilitate physician communication with hospitalized patients. Before joining Northwell in 2005 as chair of urology, Dr. Kavoussi completed his medical degree at the State University of New York at Buffalo. He obtained his urologic training at Washington University of St. Louis and, directly following residency, was named chief of urology at the Jewish Hospital of St. Louis. In 1991, he was appointed assistant professor at Harvard School of Medicine and director of endourology at the Brigham and Women's Hospital. In 1993, he joined the faculty of Johns Hopkins University School of Medicine, where he was vice chairman of urology and named a Patrick C. Walsh Distinguished Professor. Dr. Kavoussi values a team approach to care, and often collaborates with other specialists to create personalized and comprehensive treatment plans. His patients appreciate his easygoing personality and thoughtfulness. As the Waldbaum-Gardner Distinguished Professor of Urology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Dr. Kavoussi is passionate about training the next generation of surgeons. He has presented his work and given live surgical demonstrations at conferences around the world and has more than 500 academic publications. Dr. Kavoussi is rated as an Advanced provider by MediFind in the treatment of Familial Prostate Cancer. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Nephrectomy, and Reconstructive Urology Surgery.

Clary Evans is a Radiation Oncologist in Lake Success, New York. Dr. Evans is rated as an Advanced provider by MediFind in the treatment of Familial Prostate Cancer. Her top areas of expertise are Familial Prostate Cancer, Prostate Cancer, Muscle Invasive Bladder Cancer, and Breast Cancer.

Assistant Professor of Radiation MedicineThe Center for Head & Neck OncologyNorthShore-LIJ-Stereotactic-Radiation-CenterHofstra North Shore- LIJ School of Medicine. Dr. Ghaly is rated as an Advanced provider by MediFind in the treatment of Familial Prostate Cancer. His top areas of expertise are Laryngeal Cancer, Adenoid Cystic Carcinoma, Olfactory Neuroblastoma, and Teratocarcinosarcoma.

Dr. Simon J Hall MD is a board certified urologist with Fellowship training in Urologic Oncology. His clinical interests include the diagnosis and treatment of Prostate, Bladder and Kidney cancers. He is especially interested in Active Surveillance of men with prostate cancer and men and women with incidentally found small renal masses and the creation of continent urinary reconstructions for patients who need to undergo cystectomy for Bladder cancer. Furthermore, Dr. Hall has a keen interest in treating patients with recurrent prostate cancer following definitive therapy. He believes that objective & balanced communication with the patient and family is the key to decision making and individualized care. Over the years Dr. Hall has been named as Best Doctor, both nationally and regionally, by organizations such as Castle Connolly, SuperDoctors and New York Magazine. Dr. Hall s research has focused of new therapies for prostate and bladder cancer; he has participated in numerous clinical trials, some of which generated data resulting in FDA approval of Sipleucel-T (Provenge) and enzulutamide (Xtandi). He oversees a laboratory investigating novel approaches to negating the Androgen Receptor, an important key driver of castration resistant prostate cancer. Decision making and improved methods of clinical care for patients with bladder and prostate cancer are important aspects of his research interests in collaboration with Dr. Michael Diefenbach, a behavioral scientist in the Departments of Urology & Medicine at NS-LIJ. He has authored or co-authored nearly 70 peer reviewed articles in Journals such as Journal of Urology, Urology, British Journal of Urology, Clinical Cancer Research and Science. Dr. Hall received his MD from the College of Physicians & Surgeons of Columbia University. He then completed two years of Surgery training at the Mount Sinai Medical Center followed by a four year residency in Urology at Boston University School of Medicine. This was followed by a 2 year fellowship in Urologic Oncology in the Scott Department of Urology at Baylor College of Medicine. Prior to joining the Smith Institute for Urology, he served on the faculty of Icahn School of Medicine at Mount Sinai for 18 years, holding various positions including Kyung Hyun Kim MD Chair of Urology and the Director of the Deane Prostate Health & Research Center. Dr. Hall is rated as an Advanced provider by MediFind in the treatment of Familial Prostate Cancer. His top areas of expertise are Muscle Invasive Bladder Cancer, Prostate Cancer, Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery.

David Chan is a Urologist in Lake Success, New York. Dr. Chan is rated as an Advanced provider by MediFind in the treatment of Familial Prostate Cancer. His top areas of expertise are Enlarged Prostate (BPH), Obstructive Uropathy, Boils, Ureteroscopy, and Prostatectomy.

Dr. Rofeim joined the medical staff of the Smith Institute for Urology and the Hofstra NS-LIJ School of Medicine in July 2012 after being in private practice in the New York area for 10 years. After completion of general surgery training at LIJ and Beth Israel Medical Centers, he continued with urology residency at LIJ Medical Center where he served as the chief resident under the mentorship of Drs. Arthur Smith and Gopal Badlani. He graduated magna cum laude from CUNY-Queens College and cum laude from SUNY-Downstate Medical Center.During his undergraduate training, he won numerous awards including the Donald E. Lancefield Prize, the Howard Hughes Summer Fellowship Award for undergraduate research, the Robert Keating Memorial Award and was included in the National Dean's List. He received the prestigious American Medical Association Physician Recognition Award and AUA/Praecis Gerald P. Murphy Scholar Award for Distinction in the study of prostate cancer. During his residency training, he won the Academic Annual Research Competition at LIJ Medical Center.He is a member of the Alpha Omega Alpha Medical Honor Society where he served as the vice president, the American Urologic Society and the New York Section of the American Urologic Society. Dr. Rofeim is a diplomate of the American Board of Urology (Board certified) and a fellow of the American College of Surgeons. He has published several articles and a book chapter in the fileds of fertility and incontinence and has presented numerous abstracts at the American Urologic Association annual meetings and other prestigious societies in topics of fertility and interstitial cystitis. Interests include:Enlarged ProstateErectile DysfunctionGeneral UrologyIncontinenceKidney StonesUrologic Cancers. Dr. Rofeim is rated as a Distinguished provider by MediFind in the treatment of Familial Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Diphallia, Enlarged Prostate (BPH), and Ureteroscopy.

Benjamin A. Gartrell, MD, is Director, Genitourinary Malignancy Program at Montefiore and an Assistant Professor of Oncology and Urology at our Albert Einstein College of Medicine. Since joining the Montefiore team in 2012, his expertise has been in treating genitourinary malignancies including prostate cancer, bladder cancer, renal cell cancer, and testicular cancer. He is also very active in translating science findings in collaboration with research colleagues at Einstein. In 2000, Dr. Gartrell received his Bachelor of Arts in Chemistry at the College of Wooster in Ohio. Following this, he attended the Northwestern University?s Feinberg School of Medicine, in Chicago, Illinois, where he received his Doctor of Medicine in 2005. His postgraduate training began in 2005 with an internship and residency in Internal Medicine at Case Western Reserve University, which he completed in 2008. He then completed a fellowship in Hematology/Oncology at Mount Sinai School of Medicine in 2012 and became Chief Fellow from 2010-2011. With a vast range of research interests, Dr. Gartrell focuses on translational research evaluating the significance of a novel immune checkpoint molecule in bladder cancer, evaluating the role of the autonomic nervous system in?prostate cancer, toxicities associated with anticancer therapies, and the impact of bone metastasis on patients with prostate cancer. His work has been published in a number of peer-reviewed journals, including the Journal of Clinical Oncology, Urologic Oncology, and European Urology. Dr. Gartrell also participates in community outreach to promote Prostate Cancer Awareness. Dr. Gartrell is rated as a Distinguished provider by MediFind in the treatment of Familial Prostate Cancer. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Clear Cell Sarcoma, Nephrectomy, and Prostatectomy.